<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05121740</url>
  </required_header>
  <id_info>
    <org_study_id>AV-APL-A-003-21</org_study_id>
    <secondary_id>2021-004966-37</secondary_id>
    <nct_id>NCT05121740</nct_id>
  </id_info>
  <brief_title>Extension Study in a Cohort of Adult Patients With COVID-19 Infection</brief_title>
  <acronym>E-APLICOV-PC</acronym>
  <official_title>Extension Study in a Cohort of Adult Patients With SARS-CoV-2 Infection Requiring Hospital Admission and Received Treatment With Plitidepsin in the APLICOV-PC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the incidence of post-COVID morbidity and&#xD;
      characterize the complications profile in patients who participated in the APLICOV-PC study.&#xD;
      APLICOV-PC study was a multicenter, randomized, proof-of-concept clinical trial to assess the&#xD;
      safety profile of 3 different dose levels of plitidepsin (1,5 mg, 2,0 mg and 2,5 mg)&#xD;
      administered three consecutive days, in adult patients with confirmed diagnosis of COVID-19&#xD;
      who require hospital admission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The APLICOV-PC proof of concept study demonstrated the antiviral activity of plitidepsin in&#xD;
      terms of reducing viral load, inducing recovery, and impact on lymphocyte reconstitution and&#xD;
      other inflammatory parameters.&#xD;
&#xD;
      A percentage of patients, which varies between 10 and 25%, continue to show symptoms at 3&#xD;
      months after contracting the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
      infection: For some of them this significantly restricts their life, requiring them to take&#xD;
      long-term sickness leave from work, and leaving them with sequelae that may continue for more&#xD;
      than one year.&#xD;
&#xD;
      With this study, Pharmamar intends to evaluate whether the treatment with plitidepsin, by&#xD;
      attaining a reduction in the viral load and a faster recovery of the patient, could have a&#xD;
      relevant impact on the emergence of sequelae resulting from the SARS-CoV-2 infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 13, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Follow up Multicentric extension study of APLICOV-PC clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.</time_frame>
    <description>Percentage of patients who developed complications related to COVID-19 infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients requiring hospital readmission</measure>
    <time_frame>Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.</time_frame>
    <description>Percentage of patients requiring hospital readmission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients requiring oxygen therapy</measure>
    <time_frame>Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.</time_frame>
    <description>Percentage of patients requiring oxygen therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of oxygen therapy</measure>
    <time_frame>From start of oxygen therapy until end of oxygen therapy, assessed up to 12 months</time_frame>
    <description>Duration of oxygen therapy mean, standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with complications</measure>
    <time_frame>Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months..</time_frame>
    <description>Percentage of patients with complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Barthel index</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>Percentage of patients at each category according to the score obtained: 0-20: Total dependence; 21-60: Severe dependence; 61-90: Moderate dependence; 91-99: Low dependence; 100: Independence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial oxygen saturation (SaO2)</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>SaO2 mean, standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of partial pressure arterial oxygen (PaO2) and fraction of inspired oxygen (FiO2)</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>PaO2/FiO2 mean, standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced vital capacity (FVC)</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>FVC mean, standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced expiratory volume 1 (FEV1)</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>FEV1 mean, standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>FEV1/FVC mean, standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffusion test</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>Diffusion test mean, standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minute walking test</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>6 minute walking test mean, standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Medical Research Council (mMRC) Dyspnea Scale</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>Percentage of patients in each category of the mMRC dyspnea scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with alterations in chest radiography</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>Percentage of patients with alterations in chest radiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with ≥grade 2 alterations in laboratory parameters</measure>
    <time_frame>At study inclusion.At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>Percentage of patients with ≥grade 2 alterations in laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with electrocardiogram alterations</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>Percentage of patients with electrocardiogram alterations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with echocardiogram / multigated acquisition scan (ECHO/MUGA) alterations</measure>
    <time_frame>At study inclusion, an average of 12 months after end of APLICOV-PC study.</time_frame>
    <description>Percentage of patients with cardiac ECHO/MUGA alterations in patients who suffered a relevant cardiac event during their participation in the APLICOV-PC study,</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>COVID-19 Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the APLICOV-PC study, patients of arm A received 1.5 mg of plitidepsin / day for 3 consecutive days (total dose 4.5 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the APLICOV-PC study, patients of arm B received 2.0 mg of plitidepsin / day for 3 consecutive days (total dose 6.0 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the APLICOV-PC study, patients of arm C received 2.5 mg of plitidepsin / day for 3 consecutive days (total dose 7.5 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 1.5 mg / day</intervention_name>
    <description>Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).</description>
    <arm_group_label>Arm A: Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 2.0 mg / day</intervention_name>
    <description>Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).</description>
    <arm_group_label>Arm B: Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin 2.5 mg / day</intervention_name>
    <description>Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).</description>
    <arm_group_label>Arm C: Experimental 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who participated in the APLICOV-PC study receiving treatment with plitidepsin&#xD;
             and who gives consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There are no exclusion criteria for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Felipe Barona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario HM Montepríncipe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Landete, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Guisado-Vasco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quironsalud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Paredes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José Jimeno, MD, PhD</last_name>
    <phone>+ 34 91 846 6036</phone>
    <email>jjimeno@pharmamar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Belen Sopesen Veramendi</last_name>
    <phone>+ 34 91 44 44 500</phone>
    <email>bsopesen@pharmamar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Roger Paredes Lario, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roger Paredes Lario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Montepríncipe</name>
      <address>
        <city>Boadilla del monte</city>
        <state>Madrid</state>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José Barberán, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Barberán, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quironsalud Madrid</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Pablo Guisado-Vasco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pablo Guisado-Vasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>María Lourdes Porras, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Lourdes Porras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <zip>280989</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Roberto Vates Gómez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Vates Gómez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel Torralba, D</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Torralba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>280029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Paloma Gijón Vidaurreta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paloma Gijón Vidaurreta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>280127</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Julio Ancochea, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julio Ancochea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Vicente Estrada, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vicente Estrada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plitidepsin</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Post-COVID morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

